Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCA036873 · 1 trial · 2 indications
Toxicities occurring during the first study drug infusion and continues through 28 days as defined in the protocol. DLTs will be assessed for severity by the investigator using CTCAE v5.0 criteria.
TEAE is any Adverse Event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.
| Arm | Type | Description |
|---|---|---|
| Part 1a Dose Escalation | EXPERIMENTAL | INCA036873 will be administered at the protocol defined dose. |
| Part 1b Dose Expansion | EXPERIMENTAL | INCA036873 will be administered at the protocol defined dose. |
| Part 1c Pharmacodynamic Cohort | EXPERIMENTAL | INCA036873 will be administered at the protocol defined dose. |
| Name | Type | Description |
|---|---|---|
| INCA036873 | DRUG | Intravenously (IV) |
Inclusion Criteria: * Age ≥18 years. * ECOG performance status of 0 or 1. * Histologically confirmed: * Clear cell renal cell carcinoma (ccRCC). * Diffuse large B-cell lymphoma (DLBCL, NOS). * High-grade B-cell lymphoma (HGBCL). * Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL). * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
INCA036873 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, with a study evaluating the drug in participants with advanced solid tumors and hematological malignancies.
INCA036873 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
INCA036873 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug in advanced solid tumors and hematological malignancies.
INCA036873 is being studied in a Phase 1 clinical trial with the identifier NCT07195916. This trial is recruiting 280 participants with advanced solid tumors and hematological malignancies across the United States, Australia, Belgium, Denmark, and Italy. The study is currently active and recruiting.
No, INCA036873 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials. The drug is being evaluated for safety and efficacy in patients with advanced solid tumors and hematological malignancies, but it has not yet received regulatory approval.